Our research
Improving options for treatment of iron deficiency anaemia for the benefit for patients
Pharmacosmos develops and markets medicines for the treatment of
iron deficiency. A research-based company, our ongoing
R&D
programme focuses on improving the options for treatment of iron
deficiency anaemia for patients and healthcare professionals.
A result of our research and development, Pharmacosmos recently
obtained approval of Monofer® (iron
isomaltoside 1000), a novel treatment for iron deficiency
anaemia.
Ongoing clinical programme in iron therapy
Our research focuses on improving treatment of iron deficiency
anaemia with Monofer® and new treatments of iron deficiency
anaemia.
Currently, Pharmacosmos has initiated three international
clinical studies focused on expanding the clinical documentation
for Monofer®.
Learn more about our ongoing clinical programme in
iron therapy